Axsome Therapeutics, Inc. (AXSM)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$305.1M
Cash & Equivalents
$20.7M
Quarterly Burn Rate
44 mo
Est. Cash Runway
$12,031M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (2 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
BUPROPION HYDROCHLORIDE, DEXTROMETHORPHAN HYDROBROMIDE
AUVELITY |
APPROVED | ADHD, Agitation, Agitation in Patients With Dementia of the Alzheimer's Type, Agitation, Psychomotor, Agitation,Psychomotor, Alzheimer Disease, Binge-Eating Disorder, Cataplexy, Cataplexy Narcolepsy, Complex Regional Pain Syndrome, Depression, Excessive Daytime Sleepiness, Excessive Daytime Somnolence, Excessive Sleepiness, Fibromyalgia, Impaired Cognitive Function, Insomnia, Major Depressive Disorder, Major Depressive Disorder (MDD), Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms, Migraine, Multiple Sclerosis, Multiple Sclerosis Fatigue, Narcolepsy, Nicotine Dependence, Obstructive Sleep Apnea, Osteoarthritis, Knee, Postpartum, Pregnant Women and Their Offspring, Reflex Sympathetic Dystrophy, Shift-work Disorder, Smoking Cessation, Smoking, Cigarette, Treatment Resistant Depression, Treatment Resistant Major Depressive Disorder |
|
MELOXICAM, RIZATRIPTAN BENZOATE
SYMBRAVO |
APPROVED | — |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-12-01 | Phase2 Readout | — |
| 2026-12-01 | Phase3 Readout | — |
| 2026-12-01 | Phase3 Readout | — |
Active Clinical Trials (9)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06413420 | SUNOSI® (Solriamfetol) Pregnancy Registry | OTHER | Recruiting | 1,731 |
| NCT06223880 | A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms | PHASE4 | Recruiting | 350 |
| NCT06878976 | Open-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder | PHASE3 | Enrolling By Invitation | 300 |
| NCT06568367 | Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN) | PHASE3 | Recruiting | 520 |
| NCT06413433 | Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol | PHASE3 | Recruiting | 450 |
| NCT07484217 | Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol | PHASE3 | Recruiting | 508 |
| NCT07398417 | Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design | PHASE3 | Recruiting | 620 |
| NCT07637162 | Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia | PHASE3 | Enrolling By Invitation | 300 |
| NCT06170970 | Solriamfetol for the Treatment of Multiple Sclerosis Fatigue | PHASE2 | Recruiting | 46 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-03 | 8-K | Axsome Therapeutics, Inc. (AXSM) (CIK 0001579428) - EX-99.1 | EDGAR |